Urticaria | Unmet need | Chronic inducible and chronic spontaneous | US/EU | 2022
Treatment of chronic spontaneous and chronic inducible urticaria is dominated by oral medications—both approved (e.g., first- and second-generation antihistamines) and off-label (e.g., DMARDs, immunosuppressants, tricyclic antidepressants). However, several of these drug classes can have serious side effects, and many patients still struggle to control their lesions. Novartis / Roche’s Xolair is the first and only FDA-approved biologic for chronic spontaneous urticaria, although other biologics are used off-label. Clinical trials of additional biological therapies are under way, but with only one biologic approved for chronic urticaria, the factors that can positively differentiate emerging drugs from current therapies remain unknown, and many unmet needs in this space remain unfulfilled.
Questions answered
- Following the approval of Xolair, what unmet needs remain in the treatment of chronic urticaria?
- Which clinical trial endpoints and nonclinical attributes are key influencers of dermatologists’ and allergists’ prescribing decisions, and which have limited impact? What are areas of hidden opportunity?
- How does Xolair perform on key treatment drivers and goals? How does its performance compare with that of frequently prescribed conventional therapies, including immunosuppressants and antihistamines?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European dermatologists and allergists for a hypothetical new chronic urticaria drug?
Product description
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 31 European dermatologists and allergists fielded in March 2022
Key companies: Novartis, Roche, Sanofi, Regeneron
Key drugs: Xolair, Dupixent, antihistamines, immunosuppressants
Content highlights: Target Product Profile (TPP) simulator based on conjoint analysis methodology; stated versus derived importance of product attributes on prescribing behavior; assessment of current drug performance against treatment drivers and goals; physician perceptions of unmet needs in the indication and related indications; analysis of remaining drug development opportunities
